Your browser doesn't support javascript.
loading
Association Between Cystic Fibrosis Severity Markers and CFTR Genotypes in Turkish Children.
Basaran, Abdurrahman Erdem; Basaran, Aysen; Kocacik Uygun, Dilara Fatma; Yilmaz, Elanur; Moballegh, Asef; Öz, Latife; Alper, Özgül; Bingöl, Aysen.
Afiliação
  • Basaran AE; Division of Pediatric Pulmonology, Akdeniz University School of Medicine, Antalya, Turkey.
  • Basaran A; Department of Pediatrics, Akdeniz University School of Medicine, Antalya, Turkey.
  • Kocacik Uygun DF; Department of Pediatrics, Division of Allergy Immunology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
  • Yilmaz E; Department of Medical Biology and Genetics, Akdeniz University, Faculty of Medicine, Antalya, Turkey.
  • Moballegh A; Department of Medical Biology and Genetics, Akdeniz University, Faculty of Medicine, Antalya, Turkey.
  • Öz L; Department of Pediatrics, Akdeniz University, Faculty of Medicine, Antalya, Turkey.
  • Alper Ö; Department of Medical Biology and Genetics, Akdeniz University, Faculty of Medicine, Antalya, Turkey.
  • Bingöl A; Division of Pediatric Pulmonology, Akdeniz University School of Medicine, Antalya, Turkey.
Turk Thorac J ; 22(6): 426-431, 2021 Nov.
Article em En | MEDLINE | ID: mdl-35110256
ABSTRACT

OBJECTIVE:

To compare class I/II cystic fibrosis transmembrane conductance regulator (CFTR) mutations to class III-V mutations with regards to cystic fibrosis disease severity markers in children. MATERIAL AND

METHODS:

This study was designed as a cross-sectional study in Antalya province, located on the south coast of Turkey. The study included 38 cystic fibrosis patients aged between 0.6 and 18 years. The CFTR genotype of the patients was categorized into 2 groups based on the presence or absence of class I or class II mutations in any of the alleles. Group I comprised 8 homozygous, 8 with unknown alleles, and 8 compound heterozygous patients, and group II comprised 11 homozygous and 3 compound heterozygous patients. The groups were analyzed in respect of cystic fibrosis disease severity markers, such as spirometry, ShwachmanKulczycki score, body mass index (BMI), sweat chloride concentration, chronic Pseudomonas aeruginosa infection, annual exacerbation frequency, and severe exacerbations requiring hospitalization during the previous year.

RESULTS:

In the comparison of group I and group II patients, a significant difference was observed in pancreas insufficiency (83.3% vs. 35.7%; P = .005), chronic P. aeruginosa infection (58.3% vs. 7.1%; P = .002), cough severity score (1.7 ± 1.1 vs. 0.9 ± 1.5; P = .029), number of severe exacerbations requiring hospitalization during the previous year (0.9 ± 1 vs. 0.3 ± 0.8; P = .03), and sweat chloride levels (76.7 ± 15.2 vs. 61 ± 22.3; P = .02). All these values were higher in group I patients. The mean BMI values (15.8 ± 2.2 vs. 17.6 ± 2.8; P = .03) were lower in group I patients.

CONCLUSION:

There seems to be a difference between class I/II CFTR mutations and class III-V mutations on the severity of the disease in cystic fibrosis patients.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Turk Thorac J Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Turk Thorac J Ano de publicação: 2021 Tipo de documento: Article